Please ensure Javascript is enabled for purposes of website accessibility

Here's Why La Jolla Pharmaceutical Shares Are Surging 12.5% Higher Today

By Todd Campbell - Dec 22, 2017 at 12:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA surprised the biopharmaceutical with good news today.

What happened

La Jolla Pharmaceutical (LJPC -2.19%) shares surged by 12.5% as of 12 p.m. EST Friday after the FDA approved the company's first commercial drug.

So what

Earlier this year, La Jolla Pharmaceutical reported positive phase 3 results data for Giapreza (formerly LJPC-501), a medicine that can help patients suffering from a life-threatening drop in blood pressure. Management filed for FDA approval shortly thereafter, but a decision from the regulator wasn't expected until Feb. 28, 2018.

A businessman speaks into a megaphone while standing in front of a monitor showing the world and stock price charts moving in different directions.


Instead, the FDA gave La Jolla Pharmaceutical and its investors a Christmas present, approving Giapreza about two months ahead of schedule. 

In trials, Giapreza successfully increased the proportion of patients achieving a mean arterial pressure of at least 75 mmHg, or a 10 mmHg increase from baseline, three hours following the initiation of treatment, without increasing the need for standard-of-care vasopressors.

Now what

The company is targeting a March 2018 launch for Giapreza, so we won't get any insight into how rapidly doctors and hospitals will add it to their treatment arsenals until the second quarter.

That said, there is an opportunity for this drug to become a meaningful source of sales for La Jolla Pharmaceutical. There's a relatively high mortality rate associated with shock patients who don't respond to existing treatment options, and the addressable market of Giapreza is on the scale of hundreds of thousands of patients per year in the U.S. alone.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

La Jolla Pharmaceutical Company Stock Quote
La Jolla Pharmaceutical Company
$3.12 (-2.19%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.